KEYLYNK-013

Placebo-controlled study of concurrent chemoradiation therapy with Pembrolizumab followed by Pembrolizumab and Olaparib in newly diagnosed, treatment-naïve limited-stage small cell lung cancer

Study Name:
Placebo-controlled study of concurrent chemoradiation therapy with Pembrolizumab followed by Pembrolizumab and Olaparib in newly diagnosed, treatment-naïve limited-stage small cell lung cancer (LS-SCLC)

Targeted Disease(s):
Lung Cancer

Purpose of Study:

This clinical trial is trying to find out if a combination of study drugs can help stop or slow down this type of cancer.

Study Dates:
December 8, 2020 - October 28, 2027

Study Location:
Nationwide

Funding Source:
Merck & Co., Inc.

ClinicalTrails.gov Identifier:
NCT04624204

Register for Trial
Asthma Educator Institute
, | Jul 11, 2022
Community Connections - RSV: The Illness on Every Parent's Radar This Season
, | Feb 08, 2023